CLDX 8-K 2026-11-05

Celldex Therapeutics, Inc. (CLDX) 8-K dated 2026-11-05 — accession 0001171843-26-007174.

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company listed on US.

Celldex Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001171843-26-007174.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported CLDX revenue for 2026-06-30 was $22.0K. Net income was -$73.5M. Revenue was up 46.7% from 2026-03-31 to 2026-06-30. CLDX currently screens at market cap $2.35B.

Not investment advice. The CLDX SEC hub lists recent forms. The stock page is the research view.